Fox Run Management’s Denali Therapeutics DNLI Stock Holding History

Fox Run Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$200K	Buy	+7,779	New	+$160K	0.03%	810
2025 Q1	–	Sell	-38,668	Closed	-$788K	–	975
2024 Q4	$788K	Buy	+38,668	New	+$990K	0.14%	252
2024 Q3	–	Sell	-24,390	Closed	-$566K	–	866
2024 Q2	$566K	Buy	+24,390	New	+$468K	0.11%	361
2023 Q3	–	Sell	-12,478	Closed	-$368K	–	766
2023 Q2	$368K	Buy	12,478 +3,561	+40%	+$100K	0.1%	375
2023 Q1	$205K	Buy	+8,917	New	+$245K	0.07%	528
2022 Q4	–	Sell	-14,977	Closed	-$460K	–	684
2022 Q3	$460K	Buy	+14,977	New	+$487K	0.18%	199

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fox Run Management's DNLI Position: Q2 2026 in Review

Fox Run Management opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 7,779 shares worth $200K. The stake represents 0.03% of the portfolio and ranks #810 among its holdings. This is a return to the name: Fox Run Management previously reported a position in DNLI as recently as Q4 2024.

Fox Run Management first reported a position in DNLI in Q3 2022 and has held it in 6 quarters since. The position peaked at $788K in Q4 2024. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Fox Run Management held 7,779 shares of Denali Therapeutics worth $200K as of Q2 2026.
Denali Therapeutics was a new Fox Run Management position in Q2 2026.
Denali Therapeutics made up 0.03% of Fox Run Management's portfolio in Q2 2026, its #810 holding.
Fox Run Management first reported a position in Denali Therapeutics in Q3 2022 and has held it in 6 quarters since.
Fox Run Management's Denali Therapeutics position peaked at $788K in Q4 2024.
294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.